Edition:
India

Cadila Healthcare Ltd (CADI.NS)

CADI.NS on National Stock Exchange of India

268.00INR
3:56pm IST
Change (% chg)

Rs1.65 (+0.62%)
Prev Close
Rs266.35
Open
Rs266.60
Day's High
Rs269.50
Day's Low
Rs261.10
Volume
1,305,723
Avg. Vol
1,558,011
52-wk High
Rs352.60
52-wk Low
Rs206.50

Latest Key Developments (Source: Significant Developments)

Cadila Healthcare Unit Gets Final U.S. FDA Nod For Fluocinonide Cream
Tuesday, 11 Feb 2020 

Feb 11 (Reuters) - Cadila Healthcare Ltd ::ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR FLUOCINONIDE CREAM.DRUG TO BE MANUFACTURED AT AT AHMEDABAD FACILITY.  Full Article

Cadila Healthcare Says FDA Audit At Ahmedabad Topical Manufacturing Facility Successfully Closed
Monday, 10 Feb 2020 

Feb 10 (Reuters) - Cadila Healthcare Ltd ::CADILA HEALTHCARE - TOPICAL MANUFACTURING FACILITY LOCATED AT AHMEDABAD GOT ESTABLISHMENT INSPECTION REPORT FROM U.S. FDA.CADILA HEALTHCARE LTD SAYS TOPICAL MANUFACTURING FACILITY HAD COMPLETED USFDA AUDIT FROM DEC 16- DEC 20 2019 WITH ZERO 483 OBSERVATIONS.CADILA HEALTHCARE - FDA AUDIT AT AHMEDABAD TOPICAL MANUFACTURING FACILITY SUCCESSFULLY CLOSED.  Full Article

India's Cadila Healthcare Dec Qtr Consol Net Profit Falls
Wednesday, 5 Feb 2020 

Feb 5 (Reuters) - Cadila Healthcare Ltd ::DEC QUARTER CONSOL NET PROFIT 3.74 BILLION RUPEES VERSUS PROFIT OF 5.11 BILLION RUPEES YEAR AGO.CONSENSUS FORECAST FOR DEC QUARTER CONSOL PROFIT WAS 3.3 BILLION RUPEES -- REFINITIV DATA.DEC QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 36.38 BILLION RUPEES VERSUS 35.78 BILLION RUPEES YEAR AGO.  Full Article

Cadila Healthcare Says USFDA Inspected Manufacturing Facility Of Unit Alidac Pharmaceuticals; No Observations Issued
Tuesday, 4 Feb 2020 

Feb 4 (Reuters) - Cadila Healthcare Ltd ::USFDA INSPECTED MANUFACTURING FACILITY OF UNIT ALIDAC PHARMACEUTICALS AT SEZ, AHMEDABAD FROM JAN 27 TO FEB 4.AT END OF INSPECTION, NO OBSERVATION (483) WAS ISSUED.  Full Article

Cadila Healthcare -Zydus Gets Approval From DCGI For Saroglitazar Magnesium
Monday, 3 Feb 2020 

Feb 3 (Reuters) - Cadila Healthcare Ltd ::CADILA HEALTHCARE LTD -ZYDUS RECEIVES APPROVAL FROM DCGI FOR SAROGLITAZAR MAGNESIUM FOR TREATMENT OF TYPE II DIABETES.  Full Article

Cadila Healthcare Gets No Observation U.S. FDA At Ahmedabad Facility Inspection
Friday, 20 Dec 2019 

Dec 20 (Reuters) - Cadila Healthcare Ltd ::NO OBSERVATION (483) IS ISSUED AT USFDA INSPECTION.INSPECTION AT TOPICAL MANUFACTURING FACILITY LOCATED IN AHMEDABAD FROM 16TH TO 20TH DECEMBER, 2019.  Full Article

Cadila Healthcare Says Inspection By US FDA Of Co's API Manufacturing Facility Located At Dabhasa, Gujarat
Friday, 6 Dec 2019 

Dec 6 (Reuters) - Cadila Healthcare Ltd ::CADILA HEALTHCARE LTD SAYS INSPECTION BY US FDA OF COMPANY''S API MANUFACTURING FACILITY LOCATED AT DABHASA, GUJARAT.CADILA HEALTHCARE - CO RECEIVED AN ESTABLISHMENT INSPECTION REPORT (EIR) WHICH STATED THAT CLASSIFICATION OF FACILITY IS "NO ACTION INDICATED (NAI)"..  Full Article

Cadila Healthcare Says Zydus Announces Regulatory Filing Of Saroglitazar Magnesium
Thursday, 5 Dec 2019 

Dec 5 (Reuters) - Cadila Healthcare Ltd ::ZYDUS ANNOUNCES REGULATORY FILING OF SAROGLITAZAR MAGNESIUM FOR TREATMENT OF NASH WITH DCGI.  Full Article

Cadila Healthcare Says Zydus Announces Second Phase 3 Trial Of Desidustat
Monday, 18 Nov 2019 

Nov 18 (Reuters) - Cadila Healthcare Ltd ::ZYDUS ANNOUNCES SECOND PHASE 3 TRIAL OF DESIDUSTAT.  Full Article

Cadila Healthcare Buys 15% Stake In Zydus Technologies
Wednesday, 13 Nov 2019 

Nov 13 (Reuters) - Cadila Healthcare Ltd ::ACQUIRED 15% EQUITY SHARE CAPITAL OF ZYDUS TECHNOLOGIES.ALSO ACQUIRED 15% COMMON STOCK OF ZYDUS NOVELTECH INC., USA.  Full Article

BRIEF-Cadila Healthcare Says Zydus Gets Final Approval From FDA For Mesalamine Suppositories

* CADILA HEALTHCARE LTD SAYS ZYDUS RECEIVES FINAL APPROVAL FROM USFDA FOR MESALAMINE SUPPOSITORIES FOR RECTAL USE, 1000 MG Source text for Eikon: Further company coverage: